Jostein Dahle

Jostein Dahle

Company: Nordic Nanovector

Job title: Chief Scientific Officer


Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates 5:00 pm

 Review CD37 as target for radioimmunotherapy Analyse preclinical and clinical data for treatment of non-Hodgkin lymphoma with the beta-emitting radioimmunoconjugate 177Lulilotomab satetraxetan (Betalutin®) Evaluate preclinical data for treatment of chronic lymphocytic leukaemia and non-Hodgkin lymphoma with the alpha emitting radioimmunoconjugate 212Pb-TCMCNNV003 (Alpha37)Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.